scholarly journals Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations

2021 ◽  
Vol Volume 16 ◽  
pp. 545-552
Author(s):  
Dana Unninayar ◽  
Sara J Abdallah ◽  
D William Cameron ◽  
Juthaporn Cowan
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Copd Exacerbations ◽  
Polyvalent Immunoglobulin

Pregnancy and depression: Exploring a new potential treatment option

2009 ◽  
Vol 11 (6) ◽  
pp. 443-446 ◽  
Author(s):  
Deborah R. Kim ◽  
Juan Gonzalez ◽  
John P. O’Reardon
Keyword(s):  
Treatment Option ◽  
Potential Treatment

scholarly journals Cannabis, a potential treatment option in pediatric IBD? Still a long way to go

2019 ◽  
Vol 12 (4) ◽  
pp. 355-361 ◽  
Author(s):  
Nienke Halbmeijer ◽  
Michael Groeneweg ◽  
Lissy De Ridder
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Pediatric Ibd

scholarly journals How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology

2019 ◽  
Vol 10 ◽  
pp. 204201881989188 ◽  
Author(s):  
Marcus May ◽  
Theodor Framke ◽  
Bernd Junker ◽  
Carsten Framme ◽  
Amelie Pielen* ◽  
...  
Keyword(s):  
Treatment Option ◽  
Microvascular Complications ◽  
Treatment Options ◽  
Sglt2 Inhibitors ◽  
Diabetic Microangiopathy ◽  
Potential Treatment ◽  
Treatment And Prevention ◽  
Clinical Complications ◽  
Sodium Glucose Cotransporter ◽  
Increased Risk

Patients suffering from type 2 diabetes are at an increased risk of developing classical microvascular complications such as retinopathy, neuropathy, and nephropathy, which represent a significant health burden. Tight control of blood glucose, blood pressure, and serum cholesterol reduce the risk of microvascular complications but effective pharmacologically targeted treatment options for the treatment and prevention of diabetic microangiopathy are still lacking. Pharmacological inhibition of sodium glucose cotransporter 2 (SGLT2) might have the potential to directly protect against microvascular complications and could represent a potential treatment option. Randomized controlled clinical proof of concept trials are needed to investigate a potential central role of SGLT2 inhibitors in the prevention of diabetic microangiopathy and its classical clinical complications of retinopathy, neuropathy, and nephropathy.

scholarly journals Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

2019 ◽  
Vol 30 ◽  
pp. v791-v792 ◽  
Author(s):  
S.V. Liu ◽  
M. Duruisseaux ◽  
K. Tolba ◽  
E. Branden ◽  
Y. Goto ◽  
...  
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Multiple Tumour

Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP)

2017 ◽  
Vol 108 ◽  
pp. 42-45 ◽  
Author(s):  
Keum Hwa Lee ◽  
Jae Hyon Park ◽  
Dong Hyun Kim ◽  
Jimin Hwang ◽  
Goeun Lee ◽  
...  
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant Mycobacterium tuberculosis

2014 ◽  
Vol 58 (12) ◽  
pp. 7557-7559 ◽  
Author(s):  
L. Davies Forsman ◽  
T. Schön ◽  
U. S. H. Simonsson ◽  
J. Bruchfeld ◽  
M. Larsson ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Treatment Option ◽  
Multidrug Resistant ◽  
Drug Resistant ◽  
Potential Treatment ◽  
Time Curve ◽  
Content Type ◽  
Extensively Drug Resistant ◽  
Concentration Time ◽  
Strain H37rv

ABSTRACTWe investigated the activity of trimethoprim-sulfamethoxazole (SXT) againstMycobacterium tuberculosis, the pathogen that causes tuberculosis (TB). The MIC distribution of SXT was 0.125/2.4 to 2/38 mg/liter for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90of sulfamethoxazole (SMX) for the pansusceptible strain H37Rv was 76 mg/liter. In an exploratory analysis using a ratio of the unbound area under the concentration-time curve from 0 to 24 h over MIC (fAUC0–24/MIC) using ≥25 as a potential target, the cumulative fraction response was ≥90% at doses of ≥2,400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.

Sign in / Sign up

Export Citation Format

Share Document